Mabvax Therapeutics (MBVX) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	13-May-15
Document And Entity Information
Entity Registrant Name	MABVAX THERAPEUTICS HOLDINGS, INC.
Entity Central Index Key	1109196
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Trading Symbol	MBVX
Entity Common Stock, Shares Outstanding		23,276,096
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$4,739,472	$1,477,143
Grants receivable	239,539	84,344
Prepaid expenses	302,155	334,629
Other current assets	400	14,675
Total current assets	5,281,566	1,910,791
Property and equipment, net	81,597	57,053
Goodwill	6,826,003	6,826,003
Other long term assets	11,017	11,017
Total assets	12,200,183	8,804,864
Current liabilities:
Accounts payable	2,066,431	1,313,247
Accrued compensation	318,815	230,381
Accrued clinical operations and site costs	516,957	494,110
Accrued lease contingency fee	590,504	590,504
Other accrued expenses	445,904	245,421
Warrant liability		92,463
Total current liabilities	3,938,611	2,966,126
Redeemable convertible preferred stock:
Redeemable convertible preferred stock, value		1,838,025
Stockholders' equity:
Common stock	125,255	28,029
Additional paid-in capital	53,077,718	24,492,450
Accumulated deficit	-44,943,783	-24,550,308
Total stockholders' equity	8,261,572	4,000,713
Total liabilities, redeemable convertible preferred stock and stockholders' equity	12,200,183	8,804,864
Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock:
Redeemable convertible preferred stock, value
Series A-1 Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock		4,029,576
Series C Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock		966
Series D Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock	$2,382

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	2,802,867	12,525,515
Common stock, shares outstanding	2,802,867	12,525,515
Series A-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized		2,763,000
Convertible preferred stock, shares issued	1,593,389	1,593,389
Convertible preferred stock, shares outstanding		1,593,389
Convertible preferred stock, liquidation preference	$2,860,233	$2,860,233
Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized		200,000
Convertible preferred stock, shares issued	96,571	96,571
Convertible preferred stock, shares outstanding		96,571
Convertible preferred stock, liquidation preference	0	0
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	238,156	238,156
Convertible preferred stock, shares outstanding	238,156	238,156
Convertible preferred stock, liquidation preference	2,382	2,382
Series B Redeemable Convertible Preferred Stock [Member] | Mab Vax [Member]
Redeemable convertible preferred stock, shares authorized	1,250,000	1,250,000
Redeemable convertible preferred stock, shares issued	1,250,000	1,250,000
Redeemable convertible preferred stock, shares outstanding	1,250,000	1,250,000
Redeemable convertible preferred stock, aggregate liquidation value	$2,627,123	$2,627,123

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Grants	$239,539	$94,900
Total revenues	239,539	94,900
Operating costs and expenses:
Research and development	1,725,893	394,238
General and administrative	980,589	673,321
Total operating costs and expenses	2,706,482	1,067,559
Loss from operations	-2,466,943	-972,659
Interest and other income (expense)	-184	-239
Change in fair value of warrant liability	19,807
Net loss	-2,447,320	-972,898
Deemed dividend on Series A-1 preferred stock	-9,017,512	-2,214,910
Deemed dividend on Series A-1 warrant	-179,411
Deemed dividend on Series B preferred stock	-8,655,998
Accretion of preferred stock dividends	-93,234	-31,934
Net loss allocable to common stockholders	($20,393,475)	($3,219,742)
Basic and diluted net loss per share	($6.25)	($12.67)
Shares used to calculate basic and diluted net loss per share	3,262,599	254,218

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (USD $)	Redeemable Convertible Preferred Stock Series B	Convertible Preferred Stock Series A-1	Convertible Preferred Stock Series C	Convertible Preferred Stock Series D	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2014	$1,838,025	$4,029,576	$966		$28,029	$24,492,450	($24,550,308)	$4,000,713
Beginning Balance, Shares at Dec. 31, 2014	1,250,000	1,593,389	96,571		2,802,867
Conversion of Series A-1 into common stock on January 10 and February 25, 2015, Shares		-64,019			38,456
Conversion of Series A-1 into common stock on January 10 and February 25, 2015, Amount		-162,968			384	162,584
Conversion of Series C into common stock on January 10, 2015, Shares			-96,571		120,714
Conversion of Series C into common stock on January 10, 2015, Amount			-966		1,207	-241
Conversion of Series B into common stock between March 3 and March 20, 2015, Shares	-106,437				276,883
Conversion of Series B into common stock between March 3 and March 20, 2015, Amount	-160,380				2,769	157,611		160,380
Accretion of redemption value for Series A-1 from January 1 to March 25, 2015, Shares
Accretion of redemption value for Series A-1 from January 1 to March 25, 2015, Amount		47,749					-47,749
Accretion of redemption value for Series B from January 1 to March 25, 2015, Shares
Accretion of redemption value for Series B from January 1 to March 25, 2015, Amount	45,485						-45,485	-45,485
Deemed dividend related to exchange of common stock for Series A-1, Series A-1 Warrants and Series B on March 25, 2015, Shares
Deemed dividend related to exchange of common stock for Series A-1, Series A-1 Warrants and Series B on March 25, 2015, Amount	8,655,998	9,196,923					-17,852,921	-8,655,998
Exchange of Series A-1, and Series A-1 Warrants into common on and Series D on March 25, 2015, Shares		-1,529,370		117,583	2,213,407
Exchange of Series A-1, and Series A-1 Warrants into common and Series D on March 25, 2015, Amount		-13,111,280		1,176	22,134	13,087,970
Exchange of Series B into common and Series D on March 25, 2015, Shares	-1,143,563			120,573	324,095
Exchange of Series B into common and Series D on March 25, 2015, Amount	-10,379,128			1,206	3,241	10,374,681		10,379,128
Private Placement Issuance of 6,661,000 shares at $0.75 per share, net of issuance costs of $281,023 on March 31, 2015, Shares					6,661,000
Private Placement Issuance of 6,661,000 shares at $0.75 per share, net of issuance costs of $281,023 on March 31, 2015, Amount					66,610	4,648,116		4,714,726
Issuance of additional common stock in March 2015 under Common Stock Purchase Agreement in relation to Financing on July 7, 2014, Shares					88,093
Issuance of additional common stock in March 2015 under Common Stock Purchase Agreement in relation to Financing on July 7, 2014, Amount					881	-881
Elimination of warrant liability in exchange transaction						72,656		72,656
Stock-based compensation						82,772		82,772
Net loss							-2,447,320	-2,447,320
Ending Balance, Amount at Mar. 31, 2015				$2,382	$125,255	$53,077,718	($44,943,783)	$8,261,572
Ending Balance, Shares at Mar. 31, 2015				238,156	12,525,515

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating activities
Net loss	($2,447,320)	($972,898)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,323	1,790
Stock-based compensation	82,772	81,442
Change in fair value of warrants	-19,807
Increase (decrease) in operating assets and liabilities:
Grants receivable	-155,195
Other receivables	2,275
Prepaid expenses and other	44,474	-11,559
Accounts payable	753,184	212,040
Accrued clinical operations and site costs	22,847	-302,773
Accrued compensation	88,434	-80,123
Other accrued expenses	200,483
Net cash used in operating activities	-1,423,530	-1,072,081
Investing activities
Purchases of property and equipment	-28,867	-1,153
Net cash used in investing activities	-28,867	-1,153
Financing activities
Issuances of preferred stock, net of issuance costs		2,973,655
Issuances of common stock, net of issuance costs	4,714,726
Net cash provided by financing activities	4,714,726	2,973,655
Net change in cash and cash equivalents	3,262,329	1,900,421
Cash and cash equivalents at beginning of year	1,477,143	354,254
Cash and cash equivalents at end of year	4,739,472	2,254,675
Supplemental disclosures of non-cash investing and financing information:
Deemed dividend on beneficial conversion feature for preferred stock	17,852,921	2,214,910
Accretion of redemption value for Series A-1 and B preferred stock	93,234	31,934
Issuance of common stock for accounts payable		240,000
Conversion of Series A-1 redeemable preferred stock into common stock	162,968
Conversion of Series C preferred stock to common stock	966
Conversion of Series B preferred stock to common stock	160,380
Exchange of Series A-1 preferred stock and warrants into common stock and Series D preferred stock	13,111,280
Exchange of Series B preferred stock and warrants into common stock and Series D preferred stock	$10,451,784

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Basis of Presentation	MabVax Therapeutics Holdings, Inc. (f.k.a. Telik, Inc. and referred to herein as “MabVax Therapeutics Holdings” or the “Company”) (OTCQB: MBVX) was incorporated in the state of Delaware on October 20, 1988. On July 8, 2014, Tacoma Acquisition Corp., a Delaware corporation and wholly owned subsidiary of MabVax Therapeutics Holdings (“Tacoma Corp.”) merged with MabVax Therapeutics, Inc., a Delaware corporation (“MabVax Therapeutics”) pursuant to an Agreement and Plan of Merger, dated May 12, 2014, by and among MabVax Therapeutics Holdings, Tacoma Corp. and MabVax Therapeutics, as amended by that certain Amendment No. 1 to the Merger Agreement, dated June 30, 2014, by and among the parties thereto and by that certain Amendment No. 2 to the Merger Agreement, dated July 7, 2014, by and among the parties thereto (such agreement as amended, the “Merger Agreement”; such merger, the “Merger”). Unless the context otherwise requires, references to “we,” “our,” “us,” or the “Company” in this Quarterly Report mean MabVax Therapeutics Holdings on a condensed consolidated financial statement basis with our wholly-owned subsidiary following the Merger, MabVax Therapeutics, as applicable. On October 9, 2014 FINRA approved our stock symbol change request and the Company began trading under the symbol MBVX (OTCQB: MBVX) on October 10, 2014.
	The balance sheet data at December 31, 2014, has been derived from audited financial statements at that date. It does not include, however, all of the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements.
	We are a clinical stage biopharmaceutical company engaged in the discovery, development and commercialization of proprietary human monoclonal antibody products and vaccines for the treatment of a variety of cancers. We have discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Therapeutic vaccines under development were discovered at Memorial Sloan Kettering Cancer Center (“MSKCC”), and are exclusively licensed to MabVax Therapeutics. We operate in only one business segment.
	We plan to continue developing MabVax Therapeutics’ pre-Merger pipeline. And are continuing to evaluate the technology and development programs that were under way at MabVax Therapeutics Holdings prior to the Merger. We are terminating unwanted patent applications, and stopping the maintenance fees and patent prosecutions as they come due for the Telintra development program that was in place at MabVax Therapeutics Holdings prior to the Merger.
	We have incurred net losses since inception and expect to incur substantial losses for the foreseeable future as the Company continues research and development activities. To date, we have funded operations primarily through government grants, the sale of preferred stock and equity securities, non-equity payments from collaborators and interest income. The process of developing the Company’s products will require significant additional research and development, preclinical testing and clinical trials, as well as regulatory approval. We expect these activities, together with general and administrative expenses, to result in substantial operating losses for the foreseeable future. We will not receive substantial revenue unless the Company or its collaborative partners complete clinical trials, obtain regulatory approval and successfully commercialize one or more products; or the Company licenses its technology after achieving one or more milestones of interest to a potential partner.
	The accompanying unaudited condensed consolidated financial statements were prepared using GAAP for interim financial information and the instructions to Regulation S-X. While these statements reflect all normal recurring adjustments which are, in the opinion of management, necessary for a fair presentation of the results of the interim period, they do not include all information or notes required by GAAP for annual financial statements and should be read in conjunction with the Audited Financial Statements of MabVax Therapeutics Holdings for the year ended December 31, 2014, filed in our Annual Report on Form 10-K on March 31, 2015.
	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
	Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606). ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. Additionally, this update supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition-Construction-Type and Production-Type Contracts.” The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It is effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities may choose from two adoption methods, with certain practical expedients. We are currently reviewing this standard to assess the impact on the Company’s future financial statements and evaluating the available adoption methods.
	In June 2014, the FASB issued ASU No. 2014-12, “Compensation—Stock Compensation” (Topic 718): “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. ASU No. 2014-12 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. We are currently reviewing this standard to assess the impact on the Company’s future financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, (“ASU 2014-15”), “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. Certain disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of the updated standard on the financial statements and disclosures.

Liquidity_and_Going_Concern

Liquidity and Going Concern	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Liquidity and Going Concern	The accompanying condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.  As reflected in the accompanying condensed consolidated financial statements, the Company had a net loss of $2,447,320, net cash used in operating activities of $1,423,530, net cash used in investing activities of $28,867, and net cash provided by financing activities of $4,714,726 for the three months ended March 31, 2015. As of March 31, 2015, the Company had $4,739,472 in cash and cash equivalents and an accumulated deficit of $44,943,783.
	On March 31, 2015 and April 10, 2015, the Company closed on a financing transaction by entering into separate subscription agreements (the “Subscription Agreements”) with accredited investors (the “Investors”) relating to the issuance and sale of an aggregate of  $11,714,501 of units (the “Units”) at a purchase price of $0.75 per Unit, with each Unit consisting of one share of the Company’s common stock, par value $0.01 per share  (or, at the election of any Investor who, as a result of receiving common stock would hold in excess of 4.99% of the Company’s issued and outstanding common stock, shares of the Company’s newly designated 0% Series E Convertible Preferred Stock  and a thirty month warrant  to purchase one half of one share of common stock at an initial exercise price of $1.50 per share, as further described in the Notes to Financial Statements – Equity, (the “Private Placement”).
	The initial closing of the Private Placement took place on March 31, 2015, in which the Company sold an aggregate of $4,995,750 of Units. Following the initial closing the Company entered into separate reconfirmation agreements with the Investors in order to extend the initial closing date, increase the offering amount, and adopt a lockup agreement (the “Lockup Agreement”) which was entered by all Investors who elected to continue their investment.  The second closing was completed on April 10, 2015 in which the Company completed entering into the remaining separate Subscription Agreements for an additional $6,718,751 of Units. Of the Subscription Agreements accepted, Investors elected, and the Company issued, $2,500,000 of Units consisting of Series E Convertible Preferred Stock on April 10, 2015.  Of the total cash received in the second closing on April 10, 2015, $3,500,000 is being held in escrow under the terms of an escrow agreement with Signature Bank, N.A (the “Escrowed Funds”) pending the approval of a representative of one of the lead investors to join the board, or 10 weeks thereafter, unless released sooner or extended.
	The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) continues to identify and advance a number of potential drug candidates into clinical and preclinical development activities, (ii) initiates manufacturing of its lead antibody candidate 5B1 and continues to fund its operations, and (iii) expands its corporate infrastructure, including the costs associated with being a public company.  With this Private Placement, management believes that the Company has sufficient funds to meet its obligations to May 2016 if funds are released from escrow, and to November 2015, if funds are not released from the Escrowed Funds.
	The Company plans to continue to fund its losses from operations and capital funding needs through equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.
	If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. As of March 31, 2015, cash balance of approximately $4,557,000 exceeded Federally insured limits. The Company has not experienced any losses on such accounts.

Fair_value_of_financial_instru

Fair value of financial instruments	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Fair value of financial instruments	The Company’s financial instruments consist of cash and cash equivalents, grants receivable, prepaid expenses and other current assets and accounts payable, all of which are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.

Convertible_Preferred_Stock_Co

Convertible Preferred Stock, Common Stock and Warrants	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Convertible Preferred Stock, Common Stock and Warrants	Series A-1 preferred stock and common warrants
	As of March 31, 2015, and December 31, 2014, there were no shares and 1,593,389 shares of Series A-1 preferred stock outstanding, and no Series A-1 warrants and 1,280,047 Series A-1 warrants to purchase common stock at $3.62 per share outstanding, respectively.  Both the preferred stock and the warrants had price protection if there were to be a financing at a price lower than their conversion price or exercise price, requiring adjustment as further described in the Company’s annual report on Form 10-K.  The Series A-1 preferred stock and warrants were initially structured as Series C-1 preferred stock and common warrants prior to the Merger, and were converted from Series C-1 to Series A-1 preferred stock and warrants at the time of the Merger.
	Series B Preferred Stock
	As of March 31, 2015, and December 31, 2014, there were no shares and 1,250,000 shares of Series B preferred stock and no Series B warrants and 78,125 Series B warrants to purchase common stock at $1.57 a share outstanding, respectively.  Both the preferred stock and the warrants had price protection if there were to be a financing at a price lower than their conversion price or exercise price, requiring adjustment as further described in the Company’s annual report on Form 10-K.  As of December 31, 2014, the warrant liability was $92,463.
	As a result of the Series B warrants’ anti-dilution provision, the Series B warrants were recorded as a current liability in the amount of $92,463 on our condensed consolidated balance sheet as of December 31, 2014.  On March 25, 2015, the Series B warrants were re-valued at $72,656 prior to being exchanged into shares of common stock and Series D convertible preferred stock on a one for one basis and the warrant liability was eliminated and the Company recorded a gain of $19,807 for the three months ended March 31, 2015.
	Dividends on Preferred Stock
	The Company immediately recognizes the changes in the redemption value on preferred stock as they occur and the carrying value of the security is adjusted to equal what the redemption amount would be as if redemption were to occur at the end of the reporting date based on the conditions that exist as of that date. The value adjustment made to the redemption value and preferred stock dividends for the three months ended March 31, 2015, was an increase of $93,234.
	Conversion of Preferred Stock into Common Stock
	During the three months ended March 31, 2015, holders of Series A-1, Series B, and Series C preferred stock converted 64,019, 106,437, and 96,571 shares into 38,456, 276,883, and 120,714 shares of common stock, respectively.
	Exchange of Series A-1 and Series B Preferred Stock and Warrants into Common Stock and Series D Preferred Stock
	On March 25, 2015, the Company entered into separate exchange agreements with certain holders of the Company’s Series A-1 preferred stock and Merger warrants (the “Series A-1 Exchange Securities”) and holders of the Company’s Series B preferred stock and Series B warrants (the “Series B Exchange Securities” and, collectively with the Series A-1 Exchange Securities, the “Exchange Securities”), all previously issued by the Company. Pursuant to the exchange agreements, the holders exchanged the Exchange Securities and relinquished any and all other rights they may have had pursuant to the Exchange Securities, their respective governing agreements and certificates of designation, including any related registration rights, in exchange for an aggregate of 2,537,502 shares of the Company’s common stock and an aggregate of 238,156 shares of the Company’s newly designated Series D Convertible preferred stock (the “Series D preferred stock”), convertible into 23,815,600 shares of common stock.  No cash was exchanged in the transaction.  The Company recorded deemed dividends of $9,017,512, $8,655,998 and $179,411 representing the excess fair value of the common stock issued over the original conversion terms of the Series A-1 and B preferred stock as part of the consideration for elimination of the Series A-1, Series B preferred stock and Series A-1 warrant, respectively.
	Additionally, for as long as a certain principal holder of Exchange Securities holds securities issued pursuant to the Exchange Agreements, subject to certain exceptions, the Company is restricted from issuing any shares of common stock or securities convertible into common stock, enter into any equity line of credit or issue any floating or variable priced equity linked instrument.
	No commission or other payment was received by the Company in connection with the exchange agreements.
	Series D Preferred Stock
	As of March 31, 2015, there were 238,156 shares of Series D preferred stock issued and outstanding which are convertible into 23,815,600 shares of common stock.
	As contemplated by the exchange agreements and as approved by the Company’s Board of Directors, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (the “Series D Certificate of Designations”), on March 25, 2015. Pursuant to the Series D Certificate of Designations, the Company designated 1,000,000 shares of its blank check preferred stock as Series D preferred stock. Each share of Series D preferred stock has a stated value of $0.01 per share. In the event of a liquidation, dissolution or winding up of the Company, each share of Series D preferred stock will be entitled to a per share preferential payment equal to the stated value. Each share of Series D preferred stock is convertible into 100 shares of common stock. The conversion ratio is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company is prohibited from effecting the conversion of the Series D preferred stock to the extent that, as a result of such conversion, the holder beneficially would own more than 4.99% (provided that certain investors elected to block their beneficial ownership initially at 2.49% in the Exchange Agreements), in the aggregate, of the issued and outstanding shares of the Company’s common stock calculated immediately after giving effect to the issuance of shares of common stock upon the conversion of the Series D preferred stock. Each share of Series D preferred stock entitles the holder to vote on all matters voted on by holders of common stock. With respect to any such vote, each share of Series D preferred stock entitles the holder to cast such number of votes equal to the number of shares of common stock such shares of Series D preferred stock are convertible into at such time, but not in excess of the beneficial ownership limitations.
	As of March 25, 2015, pursuant to the terms of the exchange agreements, the MabVax Therapeutics Securities Purchase Agreement, Series A-1 Registration Rights Agreement, the Series B Purchase Agreement and the Series B Registration Rights Agreement, all of which have been described as part of the Company’s annual report on Form 10-K, were terminated, and all rights covenants, agreements and obligations contained therein, are of no further force or effect.
	MabVax Common Stock Financing
	On March 31, 2015 the Company entered into a Private Placement and sold 6,661,000 units, consisting of 6,661,000 shares of common stock and warrants to purchase 3,33000 shares of common stock, as described below, and received proceeds of $4,714,726, net of $281,023 in issuance costs and warrants to purchase one-half of one share of common stock for each Unit.  The Units were sold at a price of $0.75 per Unit.
	For purchasers who would hold 5% or more of the Company’s common stock by entering into the Private Placement, they may elect instead of common stock, shares of the Company’s Series E Convertible preferred stock, par value $0.01 per share (the “Series E preferred stock”) convertible into an equivalent number of shares of such common stock.
	The warrants are exercisable upon issuance and expire 30 months thereafter and may be exercised for cash or on a cashless basis. The warrants have a per share exercise price of $1.50, subject to certain adjustments typical of warrants, namely stock splits, dividends and reverse-splits. The Company is prohibited from effecting the exercise of the warrants to the extent that, as a result of such exercise, the holder beneficially would own more than 4.99% in the aggregate, of the issued and outstanding shares of the Company’s common stock calculated immediately after giving effect to the issuance of shares of common stock upon the exercise of the warrants.
	In connection with the Private Placement, the Company also entered into a Registration Rights Agreement with the investors in the Private Placement Pursuant to which the Company has agreed to file a registration statement with the SEC covering resales of up to 25% of common stock issued under the Subscription Agreements and shares issuable upon conversion of the Series E preferred stock, in the event the investors elect to receive Series E preferred stock instead of common stock (together, the “Registrable Securities”), no later than 60 days following the final closing date of the Private Placement, and to use its commercially reasonable best efforts to have such registration statement declared effective with 120 days after filing. The Company will bear all expenses of such registration of the resale of the Registrable Securities.  Investors in the Private Placement also may be required under certain circumstances to agree to refrain from resales of a percentage of their securities upon request of an underwriter or placement agent in a future offering. The liquidated damages for failure to achieve effectiveness of the Registerable Securities is 1% a month 120 days after filing, and provided management has not used commercially reasonable best efforts to have the registration statement declared effective within that timeframe.
	Except for certain issuances, for a period beginning on the closing date of the Private Placement and ending on the date that is the earlier of (i) 24 months from the final closing date of the Private Placement, (ii) the date the Company consummates a financing (excluding proceeds from the Private Placement) in which the Company receives gross proceeds of at least $10,000,000 and (iii) the date the common stock is listed for trading on a national securities exchange (such period until the earlier date, the “Price Protection Period”), in the event that the Company issues any shares of common stock or securities convertible into common stock at a price per share or conversion price or exercise price per share that is less than $0.75 (a “Lower Price Issuance”), the Company shall issue to the investors in the Private Placement such additional number of shares of common stock such that the investor shall own an aggregate total number of shares of common stock as if they had purchased the Units at the price of the lower price issuance. No adjustment in the Warrants is required in connection with a Lower Price Issuance.
	The Company has also granted each investor prior to the expiration of 24 months following the final closing date of the Private Placement, a right of participation in the Company’s financings.
	In the event the Company conducts certain private or public offerings of its securities, each investor has agreed, if requested by the underwriter or placement agent so engaged by the Company in connection with such offering, to refrain from selling any securities of the Company for a period of up to 60 days.
	Series E Preferred Stock
	As of March 31, 2015, there were no shares of Series E preferred stock issued and outstanding.
	As approved by the Company’s Board of Directors, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible preferred stock (the “Series E Certificate of Designations”), on March 30, 2015. Pursuant to the Series E Certificate of Designations, the Company designated 100,000 shares of its blank check preferred stock as Series E preferred stock.
	The shares of Series E preferred stock are convertible into shares of common stock based on a conversion calculation equal to the stated value of such Preferred Share, plus all accrued and unpaid dividends, if any, on such share of Series E preferred stock, as of such date of determination, divided by the conversion price. The stated value of each share of Series E preferred stock is $75 and the initial conversion price is $0.75 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. In addition, during the Price Protection Period, in the event the Company issues or sells, or is deemed to issue or sell, shares of common stock at a per share price that is less than the conversion price then in effect, the conversion price shall be reduced to such lower price, subject to certain exceptions. The Company is prohibited from effecting a conversion of the share of Series E preferred stock to the extent that, as a result of such conversion, such holder would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the Series E preferred stock, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%. Each holder is entitled to vote on all matters submitted to stockholders of the Company, and shall have the number of votes equal to the number of shares of common stock issuable upon conversion of such holder’s share of Series E preferred stock, but not in excess of beneficial ownership limitations. The share of Series E preferred stock bear no interest.
	The Company paid commissions to broker-dealers in the aggregate amount of approximately $524,000 between March 25, 2015, and April 10, 2015, in connection with the Private Placement.
	Issuance of Common Stock under Common Stock Purchase Agreement
	In connection with a financing that took place in July 2014, or the July 2014 Financing Transaction, the Company assumed certain obligations as per the original agreement to issue additional shares to investors in the July 2014 Financing Transaction if a subsequent financing was at a price per share lower than the price per share in the July 2014 Financing Transaction. The Company therefore issued on March 31, 2015, an aggregate of 88,093 shares of common stock that were required to be issued in connection with the July 2014 Financing Transaction, as a result of the lower share price in the Private Placement.

Stockbased_Activity

Stock-based Activity	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Stock-based Activity	Amendment of Equity Incentive Plan
	On March 31, 2015 the Company approved a Second Amended and Restated 2014 Employee, Director and Consultant Equity Incentive Plan (the “Plan”) to increase the number of shares reserved for issuance under the Plan from 158,073 to 8,360,789 shares of common stock. Additional changes to the Plan include:
		●	An “evergreen” provision to reserve additional shares for issuance under the Plan on an annual basis commencing on the first day of fiscal 2016 and ending on the second day of fiscal 2024, such that the number of shares that may be issued under the Plan shall be increased by an amount equal to the lesser of: (i) 8,000,000 or the equivalent of such number of shares after the administrator, in its sole discretion, has interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance with the Plan; (ii) the number of shares necessary such that the total shares reserved under the Plan equals (x) 15% of the number of outstanding shares of common stock on such date (assuming the conversion of all outstanding shares of Preferred Stock (as defined in the Plan) and other outstanding convertible securities and exercise of all outstanding warrants to purchase common stock) plus (y) 229,000; and (iii) an amount determined by the Board;
		●	Provide that no more than 3,000,000 shares may be granted to any participant in any fiscal year.
		●	Provisions to allow for performance based equity awards to be issued by the Company in accordance with Section 162(m) of the Internal Revenue Code.
	Stock-based Compensation
	Total estimated stock-based compensation expense, related to all of the Company’s stock-based payment awards recognized under ASC 718, “Compensation—Stock Compensation” was comprised of the following:
			2015		2014
	Research and development		$	41,576	$	38,628
	General and administrative			41,196		42,814
	Total share-based compensation expense		$	82,772	$	81,442
	Stock-based Award Activity
	The following table summarizes the Company’s stock option activity during the three months ended March 31, 2015:
			Options		Weighted-
			Outstanding		Average
					Exercise Price
	Outstanding at December 31, 2014			242,893	$	3.92
	Granted			-		-
	Exercised			-		-
	Forfeited/cancelled/expired			-		-
	Outstanding and expected to vest at March 31, 2015			242,893	$	3.92
	Vested and exercisable at March 31, 2015			166,254	$	3.81
	The total unrecognized compensation cost related to unvested stock option grants as of March 31, 2015, was $667,633 and the weighted average period over which these grants are expected to vest is 2.4 years. The Company has assumed a forfeiture rate of zero. The weighted average remaining contractual life of stock options outstanding at March 31, 2015, is 7.7 years.
	During the first three months of 2015, the Company made no grants of equity of any form to any director, officer, or other employees.
	Because the Company had a net operating loss carryforward as of March 31, 2015, no tax benefits for the tax deductions related to stock-based compensation expense were recognized in the Company’s Condensed Consolidated Statements of Operations. Additionally, no stock options were exercised in the three months ended March 31, 2015 and 2014.
	Common stock reserved for future issuance
	Common stock reserved for future issuance consists of the following at March 31, 2015:
	Common stock reserved for conversion of preferred stock			23,815,600
	Common stock reserved for exercise of warrants			3,330,500
	Common stock options outstanding			242,893
	Authorized for future grant or issuance under the Stock Plan			8,529,148
	Total			35,918,141

Net_Loss_per_Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Net Loss per Share	The Company calculates basic and diluted net loss per share using the weighted-average number of shares of common stock outstanding during the period.
	When the Company is in a net loss position, it excludes from the calculation of diluted net loss per share all potentially dilutive stock options, preferred stock and warrants, and the diluted net loss per share is the same as the basic net loss per share for such periods.
	The table below presents the potentially dilutive securities that would have been included in the calculation of diluted net loss per share if they were not antidilutive for the periods presented.
		As of March 31,
		2015		2014
	Stock options		242,893		194,120
	Redeemable convertible preferred stock		-		5,739,708
	Preferred stock		238,156		-
	Total		481,049		5,933,828

Contracts_and_Agreements

Contracts and Agreements	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Contracts and Agreements	Juno Therapeutics Option Agreement
	On August 29, 2014, MabVax Therapeutics entered into an Option Agreement (the “Option Agreement”) with Juno Therapeutics, Inc. (“Juno”). Pursuant to the Option Agreement, MabVax Therapeutics granted Juno the option to obtain an exclusive, world-wide, royalty-bearing license authorizing Juno to develop, make, have made, use, import, have imported, sell, have sold, offer for sale and otherwise exploit certain patents MabVax Therapeutics developed with respect to fully human antibodies with binding specificity against human GD2 or sialyl-Lewis A antigens and certain MabVax Therapeutics controlled biologic materials. Juno may exercise its option to purchase the license until the earlier of June 30, 2016 or 90 days from the date MSKCC completes its research with respect to the patents in accordance with the terms of agreements by and between MSKCC and MabVax Therapeutics.
	As of the three month period ended March 31, 2015, no revenues had been earned under the Option Agreement, however the Option Agreement remains valid and active.
	The Option Agreement may be terminated by either party (i) upon material breach of the other party if the breach is not cured within 30 days, or (ii) with 60 days’ prior written notice in the event the other party becomes the subject of a voluntary or involuntary petition in bankruptcy. Juno may terminate the Option Agreement at any time upon 30 days’ prior written notice. MabVax Therapeutics may terminate the Option Agreement if Juno, or any Juno employee or affiliate, is a party to any action or proceeding in which Juno, or any Juno employee or affiliate, opposes the patents or otherwise seeks a determination that any of the patents are invalid or unenforceable if Juno, or as applicable, its employee and/or affiliate, fails to discontinue its involvement in such an action within 10 days of receiving notice from MabVax Therapeutics.
	As consideration for the grant of the exclusive option to purchase the license, Juno paid MabVax Therapeutics a one-time up-front option fee in the low five figures. Should the option be exercised, MabVax Therapeutics would expect to negotiate with Juno to pay amounts that include MabVax Therapeutics license fees, milestone payments, and royalty-based compensation in connection with entering into a License. The terms of the license including the financial terms are expected to be agreed upon at a future date.
	Patheon Biologics LLC Agreement
	On April 14, 2014, the Company entered into a development and manufacturing services agreement with Patheon (f.k.a. Gallus Biopharmaceuticals) to provide a full range of manufacturing and bioprocessing services, including cell line development, process development, protein production, cell culture, protein purification, bio-analytical chemistry and QC testing.  Total amount of the contract is estimated at approximately $3.0 million.  For the three month period ended March 31, 2015, the Company recorded approximately $786,000 of expense associated with the agreement.
	NCI PET Imaging Agent Grant
	In September 2013, the NCI awarded the Company a SBIR Program Contract to support the Company’s program to develop a PET imaging agent for pancreatic cancer using a fragment of the Company’s 5B1 antibody (the “NCI PET Imaging Agent Grant”). The project period for Phase I of the grant award of approximately $250,000 covered a nine-month period which commenced in September 2013 and ended in June 2014.
	On August 25, 2014, the Company was awarded a $1.5 million contract for the Phase II portion of the NCI PET Imaging Agent Grant. The contract is intended to support a major portion of the preclinical work being conducted by the Company, together with its collaboration partner, MSKCC, to develop a novel Positron Emission Tomography (“PET”) imaging agent for detection and assessment of pancreatic cancer. The total contract amount for Phase I and Phase II of approximately $1,749,000 supports research work through June 2016.
	The Company records revenue associated with the NCI PET Imaging Agent Grant as the related costs and expenses are incurred. For the three month periods ended March 31, 2015 and 2014, the Company recorded $239,539 and $94,900 of revenue associated with the NCI PET Imaging Agent Grant, respectively.

Commitments_and_contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Commitments and contingencies	Litigation
	On May 30, 2014, a class action lawsuit was commenced in Santa Clara County Superior Court, State of California, on behalf of Cadillac Partners and others similarly situated, naming as defendants, MabVax Therapeutics, the Company and the Company’s directors, Hudson Bay Capital Management LP, Bio IP Ventures LLC, Hudson Bay Master Fund Ltd., and Hudson Bay IP Opportunities Master Fund LP, together the “Parties”. The suit alleged the defendants breached certain fiduciary duties, or aided and abetted a breach of fiduciary duties, in connection with the Company’s Merger with MabVax Therapeutics. In support of their purported claims, the plaintiff alleged, among other things, that the Company’s board has historically failed to fulfill its fiduciary duty to its stockholders, and claiming with respect to the Series B Private Placement and the Merger, that such transactions involved an inadequate sales process and included preclusive deal protection devices, and that the Company’s board of directors would receive personal benefits not available to its public stockholders as a result of the Merger. The plaintiff sought to enjoin the Merger and obtain damages as well as attorneys’ and expert fees and costs.
	On June 29, 2014, the parties entered into a Stipulation and Settlement (the “Settlement”), pursuant to which the Company agreed to file with the SEC certain supplemental disclosures in connection with the Merger. The Settlement is subject to certain confirmatory discovery to be undertaken by the plaintiff and to the Parties’ agreement on the payment of the plaintiff’s attorneys’ fees and expenses.
	On July 16, 2014, the Company and all other parties to the litigation entered into an agreement which, if consummated, will settle the litigation (the “Proposed Settlement”). Among many other terms, under the Proposed Settlement the Company and all defendants will receive a broad release of any and all claims pertaining to the Series B Private Placement, the Merger, the prior disclosure and a wide variety of other matters. The Proposed Settlement also calls for the parties to ask the court to, among other things, enter orders enjoining other stockholders from bringing similar actions, certifying the putative settlement class, and approving the Proposed Settlement as a fair, final, and binding resolution of the litigation. Under the Proposed Settlement, the Company and the other defendants have expressly denied the allegations of the complaint and denied engaging in any other misconduct, nor will any of them make any payment or in any respect amend the negotiated terms of the since-consummated Series B Private Placement and Merger. Finally, under the Proposed Settlement, the Company and the other defendants have not agreed to pay any legal fees, or reimburse any expenses, allegedly incurred by the plaintiffs who filed the complaint; instead, the Company expects that counsel for those plaintiffs will present any such disputed claim for legal fees and expenses to the court for resolution.
	On April 20, 2015, the Parties made an application for an Order for Notice and Scheduling of Hearing of Settlement in accordance with a Stipulation of Settlement dated as of April 20, 2015 (the “Action”), which sets forth the terms and conditions for settlement and which provides for dismissal of the Action with prejudice. The Company believes that any additional expenses that could be incurred related to the Action after March 31, 2015, will be offset by insurance co-payments covering expenses previously incurred or expected to be incurred in the Stipulation of Settlement.
	Operating Leases
	In connection with the Merger, the Company recorded a $590,504 contingent lease termination fee, in connection with the termination by MabVax Therapeutics Holdings (f.k.a. Telik, Inc.) of the master lease and sublease of the Porter Drive Facility, which is payable to ARE-San Francisco No. 24 (“ARE”), if the Company receives $15 million or more in additional financing in the aggregate, but otherwise forgiven.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Subsequent Events	Management Bonus Plan
	On April 2, 2015, the Compensation Committee of the Board of the Directors approved the 2015 Management Bonus Plan (the “Management Plan”) outlining maximum target bonuses of the base salaries of certain of the Company’s executive officers. Under the terms of the Management Plan, the Company’s Chief Executive Officer shall receive a maximum target bonus of up to 50% of his annual base salary, the Chief Financial Officer shall receive a maximum target bonus of up to 35% of his annual base salary and the Company’s Vice President shall receive a maximum target bonus of up to 25% of his annual base salary.
	On April 4, 2015, the Board approved the following Non-Employee Director Policy (the “Incumbent Director Policy”) with respect to incumbent non-employee members of the Board in the event that they are replaced before their term expires:
		●	A one-time issuance of 20,000 restricted shares of common stock;
		●	The vesting of all options and restricted stock grants held on such date; and
		●	The payment of all earned but unpaid cash compensation for their services on the Board and its committees, as of such date.
	On April 4, 2015, in connection with his resignation from the Board, Michael Wick received a one- time restricted stock grant of 20,000 shares under the Incumbent Director Policy.
	Rubin Grant
	On April 3, 2015, the Company entered into a consulting agreement with Steve Rubin pursuant to which he agreed to provide advisory services in connection with corporate strategy, licensing and business development estimated to be for a period of 12 months. In exchange for his services, the company provided him with a one-time grant of 200,000 shares of the Company’s restricted common stock.
	Ravetch Grant
	On April 4, 2015, the Board approved the issuance of an additional restricted fully vested stock award of 131,500 shares to Jeffrey Ravetch. This award is for future services covering at least one year period. The award was granted in addition to the prior award to Dr. Ravetch on April 2, 2015 of: (i) 34,250 restricted shares and (ii) options to purchase 34,250 shares of common stock with an exercise price of $2.30 per share, for a total grant of 200,000 restricted shares and options.
	Livingston Grant
	On April 4, 2015, the Board of Directors approved a restricted stock award by the Company of 1,000,000 shares of common stock to be issued to Phil Livingston, Ph.D. for his continuing service to the Company.  On May 13, 2015, the Compensation Committee of the Board clarified that the award is being granted in consideration for at least one year of Dr. Livingston’s services.  The committee further clarified that the vesting of the common stock shall be on the one-year anniversary of the Board of Directors’ approval of the award, or April 4, 2016.
	Consulting Agreement
	On April 5, 2015, the Company entered into a consulting agreement with The Del Mar Consulting Group, Inc. and Alex Partners, LLC pursuant to which such consultants shall provide investor relations services to the Company for a period of 12 months in consideration for 300,000 shares of the Company’s restricted common stock. The consultants also received an additional 200,000 shares of the Company’s restricted common stock upon the Company’s achieving a milestone based on its fully-diluted market capitalization.
	Series D Conversions
	Between April 6, 2015, and May 7, 2015, holders of Series D Preferred Stock converted 20,543 shares of Series D Preferred Stock into 2,054,300 shares of common stock.
	Private Placement
	On April 10, 2015, the Company completed the closing of the Private Placement and sold $6,718,751 of Units, of which $2,500,000 of the Units consisted of Series E preferred stock and the balance of investment consisting of 5,625,001 shares of common stock, together with warrants to all investors to purchase 4,479,167 shares of common stock at $1.50 a share.  Each Unit was sold at a purchase price of $0.75 per Unit.
	OPKO Health, Inc. (“OPKO”) was the lead investor in the Private Placement, purchasing $2,500,000 of Units consisting of Preferred Shares.
	As a condition to OPKO’s investment in the Private Placement, each of the other investors in the Private Placement agreed to execute the Lockup Agreement in favor of the Company, restricting the sale of 50% of the securities underlying the Units purchased by them for a period of 6 months and the remaining 50% prior to the expiration of 1 year following the final closing date of the Private Placement.
	On April 10, 2015, proceeds from the second closing were released and the Company agreed that $3.5 million of the net proceeds of such closing would be paid into and held under and the terms of an escrow agreement with Signature Bank, N.A pending the approval of a representative of OPKO or 10 weeks thereafter, unless released sooner or extended by the representative. In connection with the OPKO investment, Steven Rubin, Esq. was appointed advisor to the Company and has the right to take action with respect to the Escrowed Funds. The Escrowed Funds shall be returned to the applicable investors and the Company shall have no further obligation to issue Units to such investors in the event the release conditions are not met.
	Warrant Exercises
	Between April 13, 2015, and April 14, 2015, several holders of  Private Placement warrants to purchase common stock exercised their warrants on a cashless basis to purchase 1,219,780 shares of common stock by exercising 1,849,999 warrants to purchase shares of common stock in accordance with the terms of the warrant agreement.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2015
Basis Of Presentation Policies
Nature of operations and basis of presentation	MabVax Therapeutics Holdings, Inc. (f.k.a. Telik, Inc. and referred to herein as “MabVax Therapeutics Holdings” or the “Company”) (OTCQB: MBVX) was incorporated in the state of Delaware on October 20, 1988. On July 8, 2014, Tacoma Acquisition Corp., a Delaware corporation and wholly owned subsidiary of MabVax Therapeutics Holdings (“Tacoma Corp.”) merged with MabVax Therapeutics, Inc., a Delaware corporation (“MabVax Therapeutics”) pursuant to an Agreement and Plan of Merger, dated May 12, 2014, by and among MabVax Therapeutics Holdings, Tacoma Corp. and MabVax Therapeutics, as amended by that certain Amendment No. 1 to the Merger Agreement, dated June 30, 2014, by and among the parties thereto and by that certain Amendment No. 2 to the Merger Agreement, dated July 7, 2014, by and among the parties thereto (such agreement as amended, the “Merger Agreement”; such merger, the “Merger”). Unless the context otherwise requires, references to “we,” “our,” “us,” or the “Company” in this Quarterly Report mean MabVax Therapeutics Holdings on a condensed consolidated financial statement basis with our wholly-owned subsidiary following the Merger, MabVax Therapeutics, as applicable. On October 9, 2014 FINRA approved our stock symbol change request and the Company began trading under the symbol MBVX (OTCQB: MBVX) on October 10, 2014.
	The balance sheet data at December 31, 2014, has been derived from audited financial statements at that date. It does not include, however, all of the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements.
	We are a clinical stage biopharmaceutical company engaged in the discovery, development and commercialization of proprietary human monoclonal antibody products and vaccines for the treatment of a variety of cancers. We have discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Therapeutic vaccines under development were discovered at Memorial Sloan Kettering Cancer Center (“MSKCC”), and are exclusively licensed to MabVax Therapeutics. We operate in only one business segment.
	We plan to continue developing MabVax Therapeutics’ pre-Merger pipeline. And are continuing to evaluate the technology and development programs that were under way at MabVax Therapeutics Holdings prior to the Merger. We are terminating unwanted patent applications, and stopping the maintenance fees and patent prosecutions as they come due for the Telintra development program that was in place at MabVax Therapeutics Holdings prior to the Merger.
	We have incurred net losses since inception and expect to incur substantial losses for the foreseeable future as the Company continues research and development activities. To date, we have funded operations primarily through government grants, the sale of preferred stock and equity securities, non-equity payments from collaborators and interest income. The process of developing the Company’s products will require significant additional research and development, preclinical testing and clinical trials, as well as regulatory approval. We expect these activities, together with general and administrative expenses, to result in substantial operating losses for the foreseeable future. We will not receive substantial revenue unless the Company or its collaborative partners complete clinical trials, obtain regulatory approval and successfully commercialize one or more products; or the Company licenses its technology after achieving one or more milestones of interest to a potential partner.
	The accompanying unaudited condensed consolidated financial statements were prepared using GAAP for interim financial information and the instructions to Regulation S-X. While these statements reflect all normal recurring adjustments which are, in the opinion of management, necessary for a fair presentation of the results of the interim period, they do not include all information or notes required by GAAP for annual financial statements and should be read in conjunction with the Audited Financial Statements of MabVax Therapeutics Holdings for the year ended December 31, 2014, filed in our Annual Report on Form 10-K on March 31, 2015.
	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
Recent Accounting Pronouncements	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606). ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. Additionally, this update supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition-Construction-Type and Production-Type Contracts.” The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It is effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities may choose from two adoption methods, with certain practical expedients. We are currently reviewing this standard to assess the impact on the Company’s future financial statements and evaluating the available adoption methods.
	In June 2014, the FASB issued ASU No. 2014-12, “Compensation—Stock Compensation” (Topic 718): “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. ASU No. 2014-12 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. We are currently reviewing this standard to assess the impact on the Company’s future financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, (“ASU 2014-15”), “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. Certain disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of the updated standard on the financial statements and disclosures.

Stockbased_Activity_Tables

Stock-based Activity (Tables)	3 Months Ended
	Mar. 31, 2015
Stock-based Activity Tables
Stock-based Compensation	Total estimated stock-based compensation expense, related to all of the Company’s stock-based payment awards recognized under ASC 718, “Compensation—Stock Compensation” was comprised of the following:
		2015		2014
	Research and development	$	41,576	$	38,628
	General and administrative		41,196		42,814
	Total share-based compensation expense	$	82,772	$	81,442
Stock-based Award Activity	The following table summarizes the Company’s stock option activity during the three months ended March 31, 2015:
		Options		Weighted-
		Outstanding		Average
				Exercise Price
	Outstanding at December 31, 2014		242,893	$	3.92
	Granted		-		-
	Exercised		-		-
	Forfeited/cancelled/expired		-		-
	Outstanding and expected to vest at March 31, 2015		242,893	$	3.92
	Vested and exercisable at March 31, 2015		166,254	$	3.81
Common stock reserved for future issuance	Common stock reserved for future issuance consists of the following at March 31, 2015:
	Common stock reserved for conversion of preferred stock		23,815,600
	Common stock reserved for exercise of warrants		3,330,500
	Common stock options outstanding		242,893
	Authorized for future grant or issuance under the Stock Plan		8,529,148
	Total		35,918,141

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Net Loss Per Share Tables
Potentially dilutive securities
		Three Months Ended March 31,
		2015		2014
	Stock options		242,893		194,120
	Redeemable convertible preferred stock		-		5,739,708
	Preferred stock		238,156		-
	Total		481,049		5,933,828

Liquidity_and_Going_Concern_De

Liquidity and Going Concern (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	($2,447,320)	($972,898)
Net cash used for operating activities	1,423,530	1,072,081
Net cash provided by investing activities	28,867	1,153
Net cash provided by financing activities	4,714,726	2,973,655
Cash and cash equivalents	4,739,472	2,254,675	1,477,143	354,254
Accumulated deficit	$44,943,783		$24,550,308

Cash_and_Cash_Equivalents_Deta

Cash and Cash Equivalents (Details Narrative) (USD $)	Mar. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash balance exceeding FDIC limits	$4,557,000

Convertible_Preferred_Stock_Co1

Convertible Preferred Stock, Common Stock and Warrants (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Adjustment in redemption value	$93,234
Warrant liability		92,463
Financing raised through the sale and issuance of shares of common stock	88,093
Gain on warrant liability	19,807
Redeemable Convertible Preferred Stock Series B
Warrant liability	72,656	92,463
Preferred stock, shares issued	0	1,250,000
Warrants issued	0	78,125
Warrant price		$1.57
Preferred stock converted into common shares	106,437
Common stock issued upon conversion of preferred	276,883
Deemed dividends	8,655,998
Series A-1 Convertible Preferred Stock [Member]
Preferred stock, shares issued	1,593,389	1,593,389
Preferred stock, shares outstanding		1,593,389
Warrants issued	1,280,047
Warrant price	$3.62
Preferred stock converted into common shares	64,019
Common stock issued upon conversion of preferred	38,456
Deemed dividends	9,017,512
Series A-1 Convertible Preferred Stock [Member] | Warrant [Member]
Deemed dividends	179,411
Series C Convertible Preferred Stock [Member]
Preferred stock, shares issued	96,571	96,571
Preferred stock, shares outstanding		96,571
Preferred stock converted into common shares	96,571
Common stock issued upon conversion of preferred	120,714
Mab Vax [Member]
Warrant liability
Series D Preferred Stock [Member]
Preferred stock, shares issued	238,156
Preferred stock, shares outstanding	238,156
Common stock issuable upon conversion of preferred	23,815,600
MabVax Common Stock Financing [Member]
Shares issued	6,661,000
Unit sale price	$0.75
Warrants issued	333,000
Proceeds from issuance of preferred stock and warrants	4,714,726
Shares issued, issuance costs	$281,023

Stockbased_Activity_Details

Stock-based Activity (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$82,772	$81,442
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	41,576	38,628
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$41,196	$42,814

Stockbased_Activity_Detail_1

Stock-based Activity (Detail 1) (USD $)	3 Months Ended
	Mar. 31, 2015
Weighted Average Exercise Price
Weighted-Average Exercise Price, Outstanding at beginning of period	$3.92
Weighted-Average Exercise Price, Granted
Weighted-Average Exercise Price, Exercised
Weighted-Average Exercise Price, Forfeited/cancelled/expired
Weighted-Average Exercise Price, Outstanding and expected to vest at end of period	$3.92
Weighted-Average Exercise Price, Vested and exercisable at March 31, 2015	$3.81
Shares Issuable Under Options
Options Outstanding, Outstanding at beginning of period	242,893
Options Outstanding, Granted
Options Outstanding, Exercised
Options Outstanding, Forfeited/cancelled/expired
Options Outstanding, Outstanding and expected to vest at end of period	242,893
Options Outstanding, Vested and exercisable at March 31, 2015	166,254

Stockbased_Activity_Detail_2

Stock-based Activity (Detail 2)	Mar. 31, 2015
Common stock reserved for future issuance	35,918,141
Stock Plan [Member]
Common stock reserved for future issuance	8,529,148
Preferred Stock [Member]
Common stock reserved for future issuance	23,815,600
Warrant [Member]
Common stock reserved for future issuance	3,330,500
Stock Option [Member]
Common stock reserved for future issuance	242,893

Stockbased_Activity_Details_Na

Stock-based Activity (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense, options	$667,633
Unrecognized stock-based compensation expense, recognition period	2 years 4 months 24 days
Weighted average remaining Contractual term, stock options outstanding	7 years 8 months 12 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance under Plan	158,073
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance under Plan	8,360,789

Net_Loss_per_Share_Details

Net Loss per Share (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from diluted net loss per common share calculations	481,049	5,933,828
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from diluted net loss per common share calculations	238,156
Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from diluted net loss per common share calculations		5,739,708
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from diluted net loss per common share calculations	242,893	194,120

Contracts_And_Agreements_Detai

Contracts And Agreements (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue for NCI PET	$239,539	$94,900
Patheon Biologics [Member]
Expense	$786,000